Lab
Dauilmar Franco Ginoro
Dauilmar Franco Ginoro was paid $3.63M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 11% of everything it billed.
33Billing provider infoDAUILMAR FRANCO GINORO
HATILLO, PR 00659
HATILLO, PR 00659
33aNPI1689628588assigned 05/22/2006
33bProvider typeClinical Medical Laboratory
28Total paid$3.63M
24GClaims294,229
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#18 of 777
Median peer was paid$278K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,075 | $494K | |
| 2019 | 34,956 | $344K | |
| 2020 | 37,333 | $461K | |
| 2021 | 44,764 | $715K | |
| 2022 | 43,303 | $671K | |
| 2023 | 41,509 | $460K | |
| 2024incomplete | 41,289 | $483K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 11% | 9,941 | 9,061 | $407K |
| 84443 | Thyroid stimulating hormone (TSH) | 9.9% | 23,257 | 22,476 | $358K |
| 80061 | Lipid panel | 8.8% | 25,512 | 24,667 | $321K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.6% | 11,745 | 10,401 | $277K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.4% | 37,203 | 34,652 | $267K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.2% | 9,470 | 9,168 | $260K |
| 80053 | Comprehensive metabolic panel | 7.2% | 26,651 | 25,341 | $260K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.8% | 15,037 | 14,519 | $137K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.5% | 2,489 | 2,189 | $125K |
| 82274 | 3.0% | 7,381 | 7,115 | $110K | |
| 86328 | 2.3% | 3,631 | 3,403 | $85K | |
| 81000 | 2.3% | 27,349 | 26,169 | $82K |
85 more codes
| 84153 | 2.0% | 4,294 | $71K | |
| 80074 | 1.8% | 1,474 | $67K | |
| 82043 | 1.4% | 8,361 | $50K | |
| 82607 | 1.3% | 3,340 | $48K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 942 | $47K |
| 86701 | 1.3% | 5,100 | $47K | |
| 86738 | 1.3% | 3,568 | $46K | |
| 87276 | 1.2% | 3,389 | $44K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 1,350 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 1,240 | $40K |
| 84439 | 1.1% | 4,274 | $40K | |
| 87088 | <1% | 4,153 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,651 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,675 | $29K |
| 87275 | <1% | 2,225 | $29K | |
| 84436 | <1% | 4,106 | $26K | |
| 84479 | <1% | 3,793 | $23K | |
| 82378 | <1% | 1,059 | $19K | |
| 86592 | <1% | 3,879 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,275 | $14K |
| 86038 | <1% | 1,145 | $13K | |
| 85651 | <1% | 3,395 | $11K | |
| 82947 | <1% | 2,888 | $11K | |
| 85730 | <1% | 1,833 | $10K | |
| 82570 | <1% | 1,672 | $8K | |
| 86140 | <1% | 1,932 | $8K | |
| 85610 | <1% | 1,974 | $7K | |
| 85027 | <1% | 1,153 | $7K | |
| 82728 | <1% | 473 | $6K | |
| 83001 | <1% | 334 | $6K | |
| 86376 | <1% | 358 | $5K | |
| 84403 | <1% | 191 | $5K | |
| 82746 | <1% | 408 | $5K | |
| 80069 | <1% | 574 | $5K | |
| 86803 | <1% | 320 | $4K | |
| 86304 | <1% | 207 | $4K | |
| 84156 | <1% | 1,152 | $4K | |
| 80050 | General health panel | <1% | 404 | $4K |
| 82565 | <1% | 809 | $4K | |
| 86430 | <1% | 721 | $4K | |
| 86800 | <1% | 226 | $3K | |
| 86677 | <1% | 222 | $3K | |
| 84520 | <1% | 798 | $3K | |
| 86696 | <1% | 155 | $3K | |
| 83970 | <1% | 70 | $3K | |
| 82950 | <1% | 598 | $3K | |
| 84450 | <1% | 548 | $3K | |
| 84460 | <1% | 497 | $2K | |
| 80076 | <1% | 302 | $2K | |
| 83655 | <1% | 157 | $2K | |
| 82270 | <1% | 528 | $2K | |
| 82951 | <1% | 129 | $2K | |
| 84146 | <1% | 81 | $2K | |
| 84481 | <1% | 86 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 72 | $1K |
| 84550 | <1% | 308 | $1K | |
| 83550 | <1% | 149 | $1K | |
| 82465 | <1% | 298 | $1K | |
| 82670 | <1% | 43 | $1K | |
| 87177 | <1% | 156 | $969.00 | |
| 83002 | <1% | 55 | $919.48 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 134 | $919.35 |
| 86160 | <1% | 37 | $843.69 | |
| 82785 | <1% | 52 | $828.38 | |
| 84703 | <1% | 110 | $784.94 | |
| 87070 | <1% | 89 | $721.26 | |
| 84702 | <1% | 45 | $644.29 | |
| 87338 | <1% | 39 | $547.12 | |
| 86225 | <1% | 47 | $534.83 | |
| 87340 | <1% | 52 | $509.02 | |
| 82575 | <1% | 48 | $460.91 | |
| 87186 | <1% | 51 | $397.60 | |
| 86157 | <1% | 47 | $376.69 | |
| 82248 | <1% | 71 | $343.86 | |
| 82677 | <1% | 13 | $303.31 | |
| 82105 | <1% | 15 | $240.93 | |
| 86762 | <1% | 14 | $233.41 | |
| 86695 | <1% | 13 | $154.56 | |
| 84478 | <1% | 31 | $147.44 | |
| 83735 | <1% | 18 | $117.92 | |
| 83540 | <1% | 14 | $87.27 | |
| 82150 | <1% | 15 | $86.52 | |
| 83690 | <1% | 13 | $78.84 | |
| 86901 | <1% | 13 | $37.05 | |
| 86900 | <1% | 13 | $37.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRANCO GINORIO, DAWILMAR (OWNER)